Search results for "lipopeptide"

showing 10 items of 50 documents

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Peptides of the Constant Region of Antibodies Display Fungicidal Activity

2012

Synthetic peptides with sequences identical to fragments of the constant region of different classes (IgG, IgM, IgA) of antibodies (Fc-peptides) exerted a fungicidal activity in vitro against pathogenic yeasts, such as Candida albicans, Candida glabrata, Cryptococcus neoformans, and Malassezia furfur, including caspofungin and triazole resistant strains. Alanine-substituted derivatives of fungicidal Fc-peptides, tested to evaluate the critical role of each residue, displayed unaltered, increased or decreased candidacidal activity in vitro. An Fc-peptide, included in all human IgGs, displayed a therapeutic effect against experimental mucosal and systemic candidiasis in mouse models. It is in…

Antifungal AgentsErythrocyteslcsh:MedicineImmunoglobulin Gchemistry.chemical_compoundEchinocandinsMiceCaspofunginCandida albicanslcsh:ScienceCandida albicansMice Inbred BALB CMultidisciplinarybiologyCandidiasisAnimal ModelsInfectious DiseasesMedicineFemaleMalasseziaImmunoglobulin Constant RegionsResearch ArticleImmunologyMycologyMicrobial Sensitivity TestsMicrobiologyHemolysisAntibodiesMicrobiologyLipopeptidesImmune systemModel OrganismsDrug Resistance FungalmedicineAnimalsHumansBiologyCryptococcus neoformansMalasseziaCandida glabratalcsh:RImmunityTriazolesbiology.organism_classificationmedicine.diseaseImmunoglobulin ADisease Models AnimalchemistryImmunoglobulin MImmunoglobulin Gbiology.proteinCryptococcus neoformanslcsh:QSystemic candidiasisCaspofunginPeptidesPLoS ONE
researchProduct

Alternative Biosynthetic Starter Units Enhance the Structural Diversity of Cyanobacterial Lipopeptides

2019

Puwainaphycins (PUWs) and minutissamides (MINs) are structurally analogous cyclic lipopeptides possessing cytotoxic activity. Both types of compound exhibit high structural variability, particularly in the fatty acid (FA) moiety. Although a biosynthetic gene cluster responsible for synthesis of several PUW variants has been proposed in a cyanobacterial strain, the genetic background for MINs remains unexplored. Herein, we report PUW/MIN biosynthetic gene clusters and structural variants from six cyanobacterial strains. Comparison of biosynthetic gene clusters indicates a common origin of the PUW/MIN hybrid nonribosomal peptide synthetase and polyketide synthase. Surprisingly, the biosynthet…

Antifungal AgentsGenetics and Molecular BiologyCyanobacteria01 natural sciencesApplied Microbiology and BiotechnologycyanobacteriaPeptides Cyclicbiosynteesi03 medical and health scienceschemistry.chemical_compoundLipopeptidesBiosynthesisAnti-Infective AgentsBacterial ProteinsNonribosomal peptidePolyketide synthaseGene clusterPeptide SynthasessyanobakteeritGene030304 developmental biology2. Zero hungerchemistry.chemical_classification0303 health sciencesNatural productEcologybiology010405 organic chemistryLipopeptideAnabaenaYeast0104 chemical scienceschemistryBiochemistrypeptiditGenes BacterialMultigene Familybiology.proteinpeptidesbiosynthesisPolyketide SynthasesFood ScienceBiotechnology
researchProduct

Isolation and characterization of Saccharomyces cerevisiae mutants resistant to aculeacin A

1991

Aculeacin A is a lipopeptide that inhibits beta-glucan synthesis in yeasts. A number of Saccharomyces cerevisiae mutants resistant to this antibiotic were isolated, and four loci (ACR1, ACR2, ACR3, and ACR4) whose products are involved in the sensitivity to aculeacin A of yeast cells were defined. Mutants containing mutations in the four loci were also resistant to echinocandin B, another member of this lipopeptide family of antibiotics. In contrast, acr1, acr3, and acr4 mutants were resistant to papulacandin B (an antibiotic containing a disaccharide linked to two fatty acid chains that also inhibits beta-glucan synthesis), but acr2 mutants were susceptible to this antibiotic. This result …

Antifungal AgentsLlevat de cervesaGenotypeMutantSaccharomyces cerevisiaePapulacandin BSaccharomyces cerevisiaemedicine.disease_causePeptides CyclicMicrobiologyFungal ProteinsEchinocandinschemistry.chemical_compoundCell WallEchinocandin BmedicinePharmacology (medical)PharmacologyFungal proteinMutationbiologyMutagenicity TestsMembrane ProteinsLipopeptideAminoglicòsidbiology.organism_classificationYeastAnti-Bacterial AgentsAminoglucòsidsAminoglycosidesInfectious DiseaseschemistryBiochemistryGlucosyltransferasesMutationSchizosaccharomyces pombe ProteinsPeptidesResearch Article
researchProduct

Characterization of the interaction of the antifungal and cytotoxic cyclic glycolipopeptide hassallidin with sterol-containing lipid membranes.

2019

Hassallidins are cyclic glycolipopeptides produced by cyanobacteria and other prokaryotes. The hassallidin structure consists of a peptide ring of eight amino acids where a fatty acid chain, additional amino acids, and sugar moieties are attached. Hassallidins show antifungal activity against several opportunistic human pathogenic fungi, but does not harbor antibacterial effects. However, they have not been studied on mammalian cells, and the mechanism of action is unknown. We purified hassallidin D from cultured cyanobacterium Anabaena sp. UHCC 0258 and characterized its effect on mammalian and fungal cells. Ultrastructural analysis showed that hassallidin D disrupts cell membranes, causin…

Antifungal AgentskolesteroliPeptideLipopeptide01 natural sciencesBiochemistrychemistry.chemical_compoundSTRUCTURE ELUCIDATIONCandida albicansMARINE CYANOBACTERIAmammalian cellsmembrane1183 Plant biology microbiology virologychemistry.chemical_classification0303 health sciencesCell DeathMembraneGlycopeptidesLipopeptideHERBICOLIN-ADEHYDROPEPTIDE LACTONEAmino acidSterolsCholesterolMembraneBiochemistrysolunsalpaajatMitochondrial Membranesmedicine.symptomBacterial outer membraneBiophysicsmechanismAntineoplastic Agentssaponin digitoninMolecular dynamicsCyanobacteriaITURIN-A03 medical and health sciencesLipopeptidesMembrane LipidsNATURAL-PRODUCTSCell Line TumormedicineHumansPropidium iodidesyanobakteerit030304 developmental biologyantimikrobiset yhdisteet010405 organic chemistryMAJOR COMPONENTCell BiologyluonnonaineetAnabaenaSterol0104 chemical sciencesMechanism of actionchemistrylipopeptidepeptiditMOLECULAR-DYNAMICS1182 Biochemistry cell and molecular biologyDrug Screening Assays AntitumorGlycolipidsBiochimica et biophysica acta. Biomembranes
researchProduct

The structure and biosynthesis of heinamides A1-A3 and B1-B5, antifungal members of the laxaphycin lipopeptide family.

2021

Laxaphycins are a family of cyclic lipopeptides with synergistic antifungal and antiproliferative activities. They are produced by multiple cyanobacterial genera and comprise two sets of structurally unrelated 11- and 12-residue macrocyclic lipopeptides. Here, we report the discovery of new antifungal laxaphycins from Nostoc sp. UHCC 0702, which we name heinamides, through antimicrobial bioactivity screening. We characterized the chemical structures of eight heinamide structural variants A1-A3 and B1-B5. These variants contain the rare non-proteinogenic amino acids 3-hydroxy-4-methylproline, 4-hydroxyproline, 3-hydroxy-d-leucine, dehydrobutyrine, 5-hydroxyl beta-amino octanoic acid, and O-c…

BIOCHEMICAL-CHARACTERIZATIONNostocGENE-CLUSTER116 Chemical sciencesALGA ANABAENA-LAXAaminohapotPRODUCT01 natural sciencesBiochemistryCELL-PROLIFERATIONbiosynteesi03 medical and health scienceschemistry.chemical_compoundLipopeptidesBiosynthesisGene clusterPhysical and Theoretical ChemistryHYDROXYPROLINE030304 developmental biologyantimikrobiset yhdisteetchemistry.chemical_classificationWhole genome sequencing0303 health sciencesbiology010405 organic chemistryOrganic ChemistryLipopeptidePEPTIDESCYANOBACTERIAbiology.organism_classification3. Good health0104 chemical sciencesAmino acidEnzymeBiochemistrychemistrypeptiditHeterologous expressionCYCLIC LIPOPEPTIDESINHIBITORSOrganicbiomolecular chemistry
researchProduct

TLR2 and Dectin-1 Signaling in Mouse Hematopoietic Stem and Progenitor Cells Impacts the Ability of the Antigen Presenting Cells They Produce to Acti…

2020

Microbial recognition by pattern recognition receptors (PRRs) expressed on hematopoietic stem and progenitor cells (HSPCs) not only activates myelopoiesis but also programs the function of the monocytes and macrophages they produce. For instance, changes in HSPC programming modify the ability of macrophages derived from them to produce inflammatory cytokines. While HSPCs exposed to a TLR2 agonist give rise to tolerized macrophages (lower proinflammatory cytokine production), HSPCs treated with Dectin-1 ligands produce trained macrophages (higher proinflammatory cytokine production). However, nothing is known about the impact of HSPC exposure to microbes on the function of antigen presenting…

CD4-Positive T-LymphocytesOvalbuminhematopoietic stem and progenitor cellsCD4 T cellsAntigen-Presenting CellsMice Transgenicantigen presenting cellsLymphocyte Activationinnate immune memoryProinflammatory cytokineLipopeptidesCandida albicansAnimalsTLR2Lectins C-TypeProgenitor cellAntigen-presenting celllcsh:QH301-705.5CD86CD40biologyChemistryCommunicationHistocompatibility Antigens Class IIZymosanGeneral MedicineTh1 CellsHematopoietic Stem CellsAcquired immune systemToll-Like Receptor 2Cell biologyMice Inbred C57BLlcsh:Biology (General)biology.proteinCytokinesTh17 CellsMyelopoiesisCD80Dectin-1Signal TransductionCells
researchProduct

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study

2011

Objectives: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. Design: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. Setting: EPIC II included 1265 intensive care units in 76 countries. Patients: Patients in partic…

Candida albicanMaleAntifungal AgentsIron metabolism Pathogenesis and modulation of inflammation [IGMD 7]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.inventionEchinocandinschemistry.chemical_compound0302 clinical medicineRetrospective StudieCaspofunginlawCandida albicansPrevalenceAntifungal Agent030212 general & internal medicineCandida albicansFluconazoleMESH: SepsisFungemiaintensive careMedicine(all)MESH: AgedCross Infection0303 health scienceseducation.field_of_studyMESH: Middle AgedfungemiabiologyCandidiasisMiddle AgedIntensive care unitMESH: Candidiasisbacteremia; epidemiology; fungemia; intensive care; outcome assessment (health care); Aged; Antifungal Agents; Candida albicans; Candidiasis; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis; Critical Care and Intensive Care Medicine3. Good healthIntensive Care Unitsbacteremia epidemiology fungemia intensive care outcome assessment (health care)CandidiasiMESH: FluconazoleepidemiologyFemaleHumanmedicine.drugmedicine.medical_specialtySepsiIntensive Care UnitPopulationLipopeptides03 medical and health sciencesSepsisIntensive caremedicineHumansEchinocandinbacteremiaIntensive care medicineeducationMESH: PrevalenceAgedRetrospective Studiesoutcome assessment (health care)MESH: Humans030306 microbiologybusiness.industryMESH: Candida albicansMESH: EchinocandinsMESH: Cross InfectionMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Antifungal Agentsmedicine.diseasebiology.organism_classificationMESH: MalechemistryBacteremiaMESH: Intensive Care UnitsCaspofunginbusinessMESH: FemaleFluconazole
researchProduct

Self-adjuvanting C18 lipid vinil sulfone-PP2A vaccine: study of the induced immunomodulation against

2017

Despite the importance of the adjuvant in the immunization process, very few adjuvants merge with the antigens in vaccines. A synthetic self-adjuvant oleic-vinyl sulfone (OVS) linked to the catalytic region of recombinant serine/threonine phosphatase 2A from the nematode Angiostrongylus costaricensis (rPP2A) was used for intranasal immunization in mice previously infected with Trichuris muris. The animal intranasal immunization with rPP2A-OVS showed a reduction of 99.01% in the number of the nematode eggs and 97.90% in adult. The immunohistochemical analysis of the intestinal sections showed that in immunized animals with lipopeptide the mucus was significantly higher than in the other expe…

Chemokine CCL111001Gene Expressionchemical and pharmacologic phenomenachemokines199LipopeptidesMiceMice Inbred AKRAdjuvants ImmunologicAnimalsAmino Acid SequenceProtein Phosphatase 2SulfonesTrichuriasisIntestinal Mucosalipid vinyl sulfoneParasite Egg CountAdministration IntranasalChemokine CCL20Vaccines Conjugate31InterleukinsResearchHelminth Proteins200Recombinant ProteinsTrichuris muris vaccinationcytokinesTrichurisTh17 CellsFemaleSequence AlignmentResearch Articleself-assembling lipopeptide rPP2AOpen biology
researchProduct